Evidence map›Paper›PMID 32505185›Full record

ArticleDiagnostic pathology2020

A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion.

Xiaohong Xie, Xinqing Lin, Ming Liu, Yinyin Qin, Ming Ouyang, Shiyue Li, Yingying Gu, Shuyin Chen, Jianxing Xiang, Chengzhi Zhou

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xiaohong XieDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, 151 Yanjiang Road, Guangzhou, 510120, China.
Xinqing LinDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, 151 Yanjiang Road, Guangzhou, 510120, China.
Ming LiuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, 151 Yanjiang Road, Guangzhou, 510120, China.
Yinyin QinDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, 151 Yanjiang Road, Guangzhou, 510120, China.
Ming OuyangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, 151 Yanjiang Road, Guangzhou, 510120, China.
Shiyue LiDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, 151 Yanjiang Road, Guangzhou, 510120, China.
Yingying GuDepartment of Respiratory Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China.
Shuyin ChenBurning Rock Biotech, Guangzhou, 510300, China.
Jianxing XiangBurning Rock Biotech, Guangzhou, 510300, China.
Chengzhi ZhouDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, 151 Yanjiang Road, Guangzhou, 510120, China. zcz2019asco@163.com.ORCID http://orcid.org/0000-0003-0029-6879
First Affiliated Hospital of Guangzhou Medical University · CNBurning Rock Biotech (China) · CN

Funding

Guangdong High Level University Clinical Cultivation Project 2017-21020State Key Laboratory of Respiratory Disease- The Independent project SKLRD-QN-201720State Key Laboratory of Respiratory Disease- The open project SKLRD-OP-2018011Wu Jieping Medical Foundation's special funding fund for clinical research No.320.6750.18125
6 · The paper itself

Abstract

backgroundPrimary myoepithelial carcinoma of the lung is a rare subtype in lung cancer. Comprehensive molecular profiling of myoepithelial carcinoma of the lung is absent, neither was clinical evidence of targeted therapy available for this disease. Therefore, the optimal treatment regimen of this tumor needs to be established. CASE PRESENTATION: Here we present a case of a 68-year-old patient with stage IVB primary myoepithelial carcinoma of the lung who harbored EGFR exon 19 deletion and KRAS mutation and underwent icotinib targeted therapy, achieving partial response (PR) with progression free survival (PFS) of 3 months.

conclusionTo our knowledge, this study describes the first documented case of primary myoepithelial carcinoma lung cancer patient harboring EGFR exon 19 deletion and KRAS mutation, and showed clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) treatment in this patient.

Indexed as

AgedAntineoplastic AgentsCrown EthersDisease-Free SurvivalErbB ReceptorsExonsGene DeletionHumansLung NeoplasmsMaleMolecular Targeted TherapyMyoepitheliomaQuinazolinesSmokingAntineoplastic AgentsCrown EthersEGFR protein, humanErbB ReceptorsicotinibQuinazolinesEGFR 19delIcotinibLungMyoepithelial carcinomaSalivary gland type tumor

Identifiers

PMID32505185
PMCPMC7275596
OpenAlexW3033587404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.